Bison Wealth, LLC Seres Therapeutics, Inc. Transaction History

Bison Wealth, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2020 Oct 16, 2020	SELL	$3.74 - $28.74 $50,433 - $387,558	-13,485 Closed	0 $0
Q1 2020 May 04, 2020	SELL	$2.64 - $3.82 $31,109 - $45,014	-11,784 Reduced 46.63%	13,485 $48,000
Q4 2019 Feb 05, 2020	BUY	$2.99 - $4.42 $1,100 - $1,626	368 Added 1.48%	25,269 $87,000
Q3 2019 Nov 04, 2019	BUY	$2.29 - $4.16 $4,580 - $8,320	2,000 Added 8.73%	24,901 $100,000
Q2 2019 Aug 05, 2019	SELL	$2.28 - $7.35 $17,102 - $55,132	-7,501 Reduced 24.67%	22,901 $74,000

Q1 2019 May 09, 2019	SELL	$4.83 - $7.21 $13,156 - $19,640	-2,724 Reduced 8.22%	30,402 $209,000
Q4 2018 Feb 08, 2019	SELL	$4.52 - $8.88 $11,887 - $23,354	-2,630 Reduced 7.36%	33,126 $150,000
Q3 2018 Nov 09, 2018	SELL	$7.33 - $9.23 $21,990 - $27,690	-3,000 Reduced 7.74%	35,756 $271,000
Q2 2018 Aug 09, 2018	BUY	$6.91 - $9.55 $33,354 - $46,097	4,827 Added 14.23%	38,756 $333,000
Q1 2018 May 08, 2018	SELL	$7.34 - $11.16 $1,717 - $2,611	-234 Reduced 0.68%	33,929 $249,000
Q4 2017 Jan 29, 2018	BUY	$9.15 - $12.64 $312,591 - $431,820	34,163	34,163 $346,000

100

62.7M

36.9K

476K

Ticker MCRB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 124,072,000
Market Cap $89.3M
Description
Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the ...

Get notified when there are updates to the investment portfolio of Bison Wealth, LLC, based on Form 13F filings with the SEC.

Stay updated on Bison Wealth, LLC with notifications on news.